胆酶抑制剂对阿尔茨海默病的治疗效应:一种因果机器学习方法
medRxiv : the preprint server for health sciences
|February 23, 2026
概括
这项研究开发了一个新的框架来分析阿尔茨海默病 (AD) 治疗反应. 分析发现,胆酶抑制剂 (ChEIs) 没有明显的益处,这表明在某些患者中存在潜在的危害.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物统计学 生物统计学
背景情况:
- 阿尔茨海默病 (AD) 的治疗反应在个体之间有很大差异.
- 从AD的观察数据中估计异质治疗效应 (HTE) 的现有框架是有限的.
- 混偏见是分析现实世界AD治疗数据的一个主要挑战.
研究的目的:
- 开发和验证因果机器学习框架,以从观测数据中估计AD中的HTE.
- 评估胆酶抑制剂 (ChEIs) 对因AD而出现轻度认知障碍 (MCI) 的患者的影响.
- 确定可能受益或受到ChEI治疗损害的潜在患者子组.
主要方法:
- 开发了一个因果机器学习框架,包含因果图,HTE估计器和灵敏度分析.
- 将框架应用于NACC和ADNI队列数据,用于因AD而患有MCI的患者.
- 利用政策学习来估计治疗效果并确定最佳治疗策略.
主要成果:
- 对4049名 (12个月) 和2223名 (36个月) 患者的分析显示,ChEIs对认知和功能结果的长期影响为零或负.
- 检测结果显示,ChEIs对功能指标的影响略有不利,特别是在男性中,而不是女性中.
- 没有确定对ChEI治疗有益的响应子组.
结论:
- 开发的框架提供了一种可靠的方法,用于从观察AD数据中估计HTE.
- 这些发现强调了在中等大小的患者队列中检测治疗异质性的困难.
- 这种方法可以指导各种AD疗法的治疗选择,包括记忆剂和抗粉样物剂.
更多相关视频
09:47Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
1.9K
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
44.6K
相关概念视频
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
718
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
718
Alzheimer's Disease: Overview
1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.7K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.7K
Anticholinesterase Agents: Poisoning and Treatment
1.8K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.8K
Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.8K
